Karl Schwartz, Artist advocateReal-world outcomes for CD19‑directed CAR T‑cell therapy (lisocabtagene maraleucel) in patients with relapsed or refractory large B-cell #lymphoma
Eligible patients (N=1116) received liso-cel and had ≥1 effectiveness and safety assessment after infusion, including 195 in the second-line setting, 71 with sCNS, and 257 with transformed LBCL. Median age was 71.1 years (range, 21.5‒91.2), with 72.3% ≥65 years.
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma - PubMed
This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using …